secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001493152-24-011145
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M
--------------------------------------------------------------------------

- FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.
- Q4 2023 record sales of $17.7M; net loss of $0.3M vs $4.2M loss in Q4 2022.
- FY2023 net loss of $4.4M, improved from $8.1M loss in FY2022.
- Adjusted EBITDA negative $0.3M for FY2023 vs negative $7.5M in prior year; Q4 breakeven.
- Launched ALLOCYTE Plus and BIASURGE; signed exclusive license with Tufts University for peptide tech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer